Pfizer RSV vaccine may protect high-risk adults ages 18-59

Respiratory syncytial virus – viral vaccine under research Hailshadow | Istock | Getty Images A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late stage clinical trial, the company said Tuesday. The initial data suggests … Read more

Drugmakers are capping inhaler prices at $35

A woman using an inhaler.  BSIP | Universal Images Group | Getty Images Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good afternoon! Inhalers will soon get a whole lot cheaper for some Americans.  Three of the world’s largest inhaler makers have agreed to cap the … Read more

Pfizer RSV vaccine protects older adults over two seasons

Respiratory syncytial virus vial. Manjurul | Istock | Getty Images Pfizer‘s vaccine against respiratory syncytial virus maintained protection for older adults across two full seasons of the disease in an ongoing late-stage clinical trial, the company announced Thursday. The shot’s efficacy declined slightly compared with the levels of protection after one RSV season, but the … Read more

GRANOLAS stocks power Europe to record highs, drawing Magnificent 7 comparisons

The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, January 19, 2024.  Staff | Reuters Over the last 12 months, just 11 stocks made up half of the gains that powered the pan-European Stoxx 600 stock index to a record-high close on Friday. Earlier this month, Goldman Sachs … Read more

GRANOLAS stocks power Europe to record highs, drawing Magnificent 7 comparisons

The German share price index DAX graph is pictured at the stock exchange in Frankfurt, Germany, January 19, 2024.  Staff | Reuters Over the last 12 months, just 11 stocks made up half of the gains that powered the pan-European Stoxx 600 stock index to a record-high close on Friday. Earlier this month, Goldman Sachs … Read more

GSK posts blowout RSV vaccine sales, raises outlook

Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020.  Dado Ruvic | Reuters GlaxoSmithKline on Wednesday lifted its long-term outlook following the smash-hit launch of its new RSV vaccine. The shot targeting the severe and in some cases life-threatening virus booked around £1.2 billion, or $1.5 billion, in … Read more

5 things to know before the stock market opens Monday

Here are the most important news items that investors need to start their trading day: 1. Rates and robots For the main factors driving stocks, there are few bigger weeks than the one ahead. The Federal Reserve, which has so far succeeded in its push to curb inflation without triggering a recession in the U.S., … Read more

Renewed interest in ADCs will continue in 2024

Medical personnel use a mammogram to examine a woman’s breast for breast cancer. Hannibal Hanschke | dpa | Picture Alliance | Getty Images SAN FRANCISCO — An established but promising group of cancer drugs was a red-hot market in 2023, and more companies could look to the treatments to fuel growth in the year ahead. … Read more